2015 has been a turbulent year for pharma stocks. Deals have helped the sector remain in favor, but concerns about pricing and the Valeant scandal are just two of the factors that have tarred the sector's reputation, bringing valuations back down to earth.
See also: Divergence In The Drug Business: Pharmaceuticals And Biotechnology
Analysts at Credit Suisse believe that 2016 is set to be yet another volatile year for the sector, especially small- and mid-cap names. However, they believe that seven pharmaceutical names have what it takes to outperform via a combination of strong product stories, near-term pivotal catalysts, financial strength and experienced management teams.
Portola and Alkermes are the bank's top small- and mid-cap pharma picks for 2016. PTLA is awaiting the Mar...
Login required to continue reading.
Setup a free account to get access to this article (no credit card required).
View Full Article
